Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Phase 3 trial results for REVIVE-2 in patients with ABSSSIPotential cost savings opportunities with iclaprim versus vancomycinIclaprim in vitro susceptibility data NEW YORK, Feb. 21, 2018 ...
-
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel...
-
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM/NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
-
NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
-
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
-
Iclaprim met the primary endpointIclaprim was well tolerated in the study Additional data from the previously announced topline results are included in the publication NEW YORK, Dec. 21, 2017 ...
-
NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
-
1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Fibrosis Patients 2. Iclaprim Demonstrates Potent In Vitro Suppression of...
-
Iclaprim met the primary endpoint Iclaprim was well tolerated in the study NDA submission expected in the first quarter of 2018 Company to host a conference call today at 2.00 pm CET/1.00 pm BST/8:00...
-
NEW YORK, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced...